Research Scientist, In Vivo Pharmacology

Poseida Therapeutics, Inc. is searching for an outstanding Scientist to join our Nanotechnology group.  This position offers an excellent opportunity to develop delivery tools for gene therapy applications in an exciting and dynamic environment focused on cutting-edge gene editing technology. This person will be engaged in in vivo activities directed toward discovery and characterization of novel nanoparticle and other proprietary systems for delivering nucleic acids and proteins for in vivo gene therapy. This is an entry level position with the opportunity for rapid career growth.

These may include but are not limited to:

  • Design and execute studies in mice and rats in support of in vivo screening and pharmacology projects
  • Develop novel in vivo and in vitro assays to answer mechanistic questions related to delivery of gene therapy vectors
  • Attend scientific meetings, critically evaluate data, and present scientific results

Requirements, Knowledge, Skills and Abilities

  • PhD in bioengineering, pharmacology, molecular/cell biology, or other relevant field
  • Demonstrated subject matter expertise in inborn errors of metabolism and/or genetic diseases of the liver is necessary
  • Experience designing and executing studies addressing pharmacokinetic, pharmacodynamic, and/or toxicological properties of nanoparticle-enabled gene therapies is necessary
  • Solid understanding of ADME considerations relevant to nanoparticle-based nucleic acid drug formulations
  • Ability to work on in a fast paced and dynamic environment
  • Ability to travel between Poseida and vivarium (1.5 miles)

Who We Are and What We Do

Poseida is a San Diego based biotechnology leader in the development of cell and gene therapies.  We have built a wholly-owned pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Here at Poseida we are constantly innovating and growing as we advance our CAR-T therapies in the clinic and our gene therapies currently under development.  The Poseida team is passionate about the impact we are making in developing treatments, or even cures, for patients with cancer or other genetic diseases.

The company’s CAR-T product candidates are manufactured with Poseida’s non-viral piggyBac® DNA Modification System, resulting in a high percentage of stem cell memory T cells (TSCM). Tscm cells are the only T cells that are self-renewing and long-lived, potentially resulting in product candidates that are more efficacious, less toxic and more durable. Poseida is currently developing the following CAR-T product candidates:

  • P-BCMA-101 is an autologous CAR-T therapy for the treatment of relapsed/refractory multiple myeloma, currently enrolling patients for a Phase 2 registrational trial with initial dosing expected in the first half of 2019.
  • P-PSMA-101 is an autologous CAR-T product candidate targeting PSMA-specific cancer cells in castrate resistant prostate cancer, with filing of an IND anticipated in the second half of 2019.
  • P-BCMA-ALLO1 is an allogeneic, or universal donor, CAR-T product candidate, manufactured using Poseida’s proprietary Cas-CLOVER™ site specific gene editing system and is being developed as a treatment for relapsed/refractory multiple myeloma, with an IND filing anticipated by late 2019 or early 2020.
  • P-MUC1C-101 is an autologous CAR-T product candidate in late-stage preclinical development for numerous solid tumor indications, including ovarian, breast, lung, colorectal, pancreatic and renal cancers, with filing of an IND anticipated in 2020.

Poseida plans to broadly advance its current CAR-T programs and emerging pipeline programs, including gene therapies for orphan genetic diseases.